Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH
Int J Hematol. 2024 May 3. doi: 10.1007/s12185-024-03786-0. Online ahead of print.ABSTRACTWhen Epstein-Barr virus (EBV) infection is suspected, identification of infected cells is important to understand the pathogenesis, determinine the treatment strategy, and predict the prognosis. We used the PrimeFlow™ RNA Assay Kit with a probe to detect EBV-encoded small RNAs (EBERs) and multiple surface markers, to identify EBV-infected cells by flow cytometry. We analyzed a total of 24 patients [11 with chronic active EBV disease (CAEBV), 3 with hydroa vacciniforme lymphoproliferative disorder, 2 with X-linked lymphoproliferative...
Source: International Journal of Hematology - May 3, 2024 Category: Hematology Authors: Dan Tomomasa Kay Tanita Yuriko Hiruma Akihiro Hoshino Ko Kudo Shohei Azumi Mitsutaka Shiota Masayoshi Yamaoka Katsuhide Eguchi Masataka Ishimura Yuka Tanaka Keiji Iwatsuki Keisuke Okuno Asahito Hama Ken-Ichi Sakamoto Takashi Taga Kimitoshi Goto Haruka Ota Source Type: research

Protection from bleeds during physical activity in people with haemophilia: the role of factor levels: a response to Nogami et al. (2023)
Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03785-1. Online ahead of print.NO ABSTRACTPMID:38691311 | DOI:10.1007/s12185-024-03785-1 (Source: International Journal of Hematology)
Source: International Journal of Hematology - May 1, 2024 Category: Hematology Authors: Olav Versloot J van der Net K Fischer Source Type: research

Evolution of natural killer cell-targeted therapy for acute myeloid leukemia
Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778-0. Online ahead of print.ABSTRACTIn hematologic oncology, acute myeloid leukemia (AML) presents a significant challenge due to its complex genetic landscape and resistance to conventional therapies. Despite advances in treatment, including intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis for many patients with AML remains poor. Recently, immunotherapy has emerged as a promising approach to improve outcomes by augmenting existing treatments. Natural killer (NK) cells, a subset of innate lymphoid cells, have garnered attention fo...
Source: International Journal of Hematology - May 1, 2024 Category: Hematology Authors: Yuta Kaito Yoichi Imai Source Type: research

Protection from bleeds during physical activity in people with haemophilia: the role of factor levels: a response to Nogami et al. (2023)
Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03785-1. Online ahead of print.NO ABSTRACTPMID:38691311 | DOI:10.1007/s12185-024-03785-1 (Source: International Journal of Hematology)
Source: International Journal of Hematology - May 1, 2024 Category: Hematology Authors: Olav Versloot J van der Net K Fischer Source Type: research

Evolution of natural killer cell-targeted therapy for acute myeloid leukemia
Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778-0. Online ahead of print.ABSTRACTIn hematologic oncology, acute myeloid leukemia (AML) presents a significant challenge due to its complex genetic landscape and resistance to conventional therapies. Despite advances in treatment, including intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis for many patients with AML remains poor. Recently, immunotherapy has emerged as a promising approach to improve outcomes by augmenting existing treatments. Natural killer (NK) cells, a subset of innate lymphoid cells, have garnered attention fo...
Source: International Journal of Hematology - May 1, 2024 Category: Hematology Authors: Yuta Kaito Yoichi Imai Source Type: research

Clinical features of immature leukemias in children
Int J Hematol. 2024 Apr 30. doi: 10.1007/s12185-024-03771-7. Online ahead of print.ABSTRACTEarly T-cell precursor acute lymphoblastic leukemia (ETP-ALL), mixed phenotypic acute leukemia (MPAL), and acute myeloid leukemia with minimal differentiation (AML-M0) all originate from immature hematopoietic progenitor cells and have a poor prognosis. We investigated the clinical characteristics of these immature leukemias in 17 children (ETP-ALL: 8, MPAL: 5, AML-M0: 4) at seven institutions. Clinical and laboratory findings were comparable across disease types. Eleven and six patients received ALL- and AML-oriented induction chemo...
Source: International Journal of Hematology - April 30, 2024 Category: Hematology Authors: Daichi Sajiki Nao Yoshida Hideki Muramatsu Kimiyoshi Sakaguchi Naoko Maeda Norifumi Yokoyama Yuji Miyajima Makito Tanaka Yoshiyuki Takahashi Asahito Hama Source Type: research

Clinical features of immature leukemias in children
Int J Hematol. 2024 Apr 30. doi: 10.1007/s12185-024-03771-7. Online ahead of print.ABSTRACTEarly T-cell precursor acute lymphoblastic leukemia (ETP-ALL), mixed phenotypic acute leukemia (MPAL), and acute myeloid leukemia with minimal differentiation (AML-M0) all originate from immature hematopoietic progenitor cells and have a poor prognosis. We investigated the clinical characteristics of these immature leukemias in 17 children (ETP-ALL: 8, MPAL: 5, AML-M0: 4) at seven institutions. Clinical and laboratory findings were comparable across disease types. Eleven and six patients received ALL- and AML-oriented induction chemo...
Source: International Journal of Hematology - April 30, 2024 Category: Hematology Authors: Daichi Sajiki Nao Yoshida Hideki Muramatsu Kimiyoshi Sakaguchi Naoko Maeda Norifumi Yokoyama Yuji Miyajima Makito Tanaka Yoshiyuki Takahashi Asahito Hama Source Type: research

Post-transfusion purpura and adult primary thrombocytopenia
Int J Hematol. 2024 Apr 29. doi: 10.1007/s12185-024-03784-2. Online ahead of print.NO ABSTRACTPMID:38684587 | DOI:10.1007/s12185-024-03784-2 (Source: International Journal of Hematology)
Source: International Journal of Hematology - April 29, 2024 Category: Hematology Authors: Philip Murphy Source Type: research

Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies
Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775-3. Online ahead of print.ABSTRACTA 43-year-old woman was referred to our department for hematopoietic stem cell transplantation for acute myeloid leukemia, as she failed to achieve remission following induction therapy. Umbilical cord blood transplantation was initially planned; however, multiple anti-human leukocyte antigen (HLA) antibodies with a mean fluorescence intensity of over 10,000 were detected, and optimal umbilical cord blood could not be obtained. The plan was then switched to peripheral blood stem cell transplantation (PBSCT) from the patient's son, wh...
Source: International Journal of Hematology - April 27, 2024 Category: Hematology Authors: Kengo Katsuki Takayoshi Tachibana Akihiko Izumi Kumryo Kim Taisei Suzuki Masatsugu Tanaka Hideaki Nakajima Source Type: research

Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies
Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775-3. Online ahead of print.ABSTRACTA 43-year-old woman was referred to our department for hematopoietic stem cell transplantation for acute myeloid leukemia, as she failed to achieve remission following induction therapy. Umbilical cord blood transplantation was initially planned; however, multiple anti-human leukocyte antigen (HLA) antibodies with a mean fluorescence intensity of over 10,000 were detected, and optimal umbilical cord blood could not be obtained. The plan was then switched to peripheral blood stem cell transplantation (PBSCT) from the patient's son, wh...
Source: International Journal of Hematology - April 27, 2024 Category: Hematology Authors: Kengo Katsuki Takayoshi Tachibana Akihiko Izumi Kumryo Kim Taisei Suzuki Masatsugu Tanaka Hideaki Nakajima Source Type: research

Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies
Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775-3. Online ahead of print.ABSTRACTA 43-year-old woman was referred to our department for hematopoietic stem cell transplantation for acute myeloid leukemia, as she failed to achieve remission following induction therapy. Umbilical cord blood transplantation was initially planned; however, multiple anti-human leukocyte antigen (HLA) antibodies with a mean fluorescence intensity of over 10,000 were detected, and optimal umbilical cord blood could not be obtained. The plan was then switched to peripheral blood stem cell transplantation (PBSCT) from the patient's son, wh...
Source: International Journal of Hematology - April 27, 2024 Category: Hematology Authors: Kengo Katsuki Takayoshi Tachibana Akihiko Izumi Kumryo Kim Taisei Suzuki Masatsugu Tanaka Hideaki Nakajima Source Type: research

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment
Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773-5. Online ahead of print.ABSTRACTMutations in CCAAT enhancer binding protein α (CEBPA) occur in approximately 10% of patients with de novo acute myeloid leukemia (AML). Emerging evidence supports that in-frame mutations in the basic leucine zipper domain of CEBPA (CEBPAbZIP-inf) confer a survival benefit, and CEBPAbZIP-inf replaced CEBPA double mutations (CEBPAdm) as a unique entity in the 2022 World Health Organization (WHO-2022) classification and International Consensus Classification (ICC). However, challenges remain in daily clinical practice since more than 3...
Source: International Journal of Hematology - April 26, 2024 Category: Hematology Authors: Feng-Ming Tien Hsin-An Hou Source Type: research

Mendelian randomization reveals association of gut microbiota with Henoch-Sch önlein purpura and immune thrombocytopenia
Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03777-1. Online ahead of print.ABSTRACTGut microbiota have been linked to immune thrombocytopenia (ITP) and Henoch-Schönlein purpura (HSP) in recent studies, but a cause-and-effect relationship is unclear. We used Mendelian randomization (MR) to assess causal relationships between gut microbiota and HSP/ITP using summary statistics from the GWAS dataset of the international MiBioGen and FinnGen consortium. The IVW method was used as the main evaluation indicator. MR analysis of 196 intestinal flora and HSP/ITP/sTP phenotypes showed that 12 flora were potentially causally...
Source: International Journal of Hematology - April 26, 2024 Category: Hematology Authors: Chendong Jiang Shu Deng Xiaohan Ma Juan Song Jinpeng Li Enwu Yuan Source Type: research

Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
In this study, we retrospectively analyzed CMV infections in 53 patients with NDMM who received daratumumab as induction therapy. CMV infection was defined as CMV antigenemia positivity. The median age at treatment initiation was 71 years (range, 50-82 years), and 50.9% of the patients were female. The median duration of daratumumab administration was 10.0 months (range, 0.3-63.8 months). Nine patients developed CMV infection, and the cumulative incidence rate at six months was 18.1% (95% confidence interval: 8.9-30.1%). One patient experienced CMV retinitis and required antiviral therapy, while the remaining eight patient...
Source: International Journal of Hematology - April 19, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research

Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
In this study, we retrospectively analyzed CMV infections in 53 patients with NDMM who received daratumumab as induction therapy. CMV infection was defined as CMV antigenemia positivity. The median age at treatment initiation was 71 years (range, 50-82 years), and 50.9% of the patients were female. The median duration of daratumumab administration was 10.0 months (range, 0.3-63.8 months). Nine patients developed CMV infection, and the cumulative incidence rate at six months was 18.1% (95% confidence interval: 8.9-30.1%). One patient experienced CMV retinitis and required antiviral therapy, while the remaining eight patient...
Source: International Journal of Hematology - April 19, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research